aTyr Pharma, Inc.ATYRNASDAQ
Loading
Price to Sales: Premium ValuationElevated
Percentile Rank92
3Y CAGR+332.6%
5Y CAGR+202.4%
Year-over-Year Change
Price-to-sales ratio
3Y CAGR
+332.6%/yr
Annual compound
5Y CAGR
+202.4%/yr
Recent acceleration
Percentile
P92
Near historical high
vs 5Y Ago
252.8x
Strong expansion
Streak
1 yr
Consecutive declineElevated
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 383.25 | -66.5% |
| 2024 | 1143.94 | +335.4% |
| 2023 | 262.72 | +5449.8% |
| 2022 | 4.73 | - |
| 2021 | 0.00 | -100.0% |
| 2020 | 1.52 | -89.0% |
| 2019 | 13.76 | - |
| 2018 | 0.00 | - |
| 2017 | 0.00 | - |
| 2016 | 0.00 | - |